Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13785
Abstract: Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI). read more here.
Keywords: transporter inhibitors; sodium glucose; heart; glucose transporter ... See more keywords
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2286
Abstract: In 2015, the first large‐scale placebo‐controlled trial designed to assess cardiovascular safety of glucose‐lowering with sodium–glucose co‐transporter 2 (SGLT2) inhibition in type 2 diabetes mellitus raised hypotheses that the class could favourably modify not only… read more here.
Keywords: sodium glucose; cardiology; glucose transporter; heart failure ... See more keywords
Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study
Sign Up to like & getrecommendations! Published in 2019 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.4900
Abstract: To determine the risk of fractures associated with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) compared with dipeptidyl peptidase‐4 inhibitors (DPP4i). read more here.
Keywords: glucose transporter; transporter inhibitors; sodium glucose; risk fractures ... See more keywords
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-06973-3
Abstract: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and… read more here.
Keywords: glucose transporter; transporter inhibitors; sodium glucose;
Discovery and optimization of thienopyridine derivatives as novel urea transporter inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2019.03.060
Abstract: Urea transporters (UTs) play an important role in the urine concentrating mechanism and are recognized as novel targets for developing small molecule inhibitors with salt-sparing diuretic activity. Thienoquinoline derivatives, a class of novel UT-B inhibitors… read more here.
Keywords: transporter inhibitors; discovery optimization; thienopyridine derivatives; urea transporter ... See more keywords
The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in the Netherlands.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2194802
Abstract: OBJECTIVES Type-2 Diabetes Mellitus (T2DM) increases both the patient risk of cardiovascular disease (CVD) and renal outcomes, such as chronic kidney disease (CKD). Recent clinical trials of the glucose-lowering drug-class of sodium-glucose co-transporter-2 inhibitors (SGLT2is)… read more here.
Keywords: health; glucose transporter; guideline; impact ... See more keywords
Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.
Sign Up to like & getrecommendations! Published in 2022 at "Metabolic syndrome and related disorders"
DOI: 10.1089/met.2022.0004
Abstract: The introduction of sodium glucose transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus treatment has shown an unexpectedly significant improvement in heart disease outcome trials. Although they have very different modes… read more here.
Keywords: glucose transporter; metabolic syndrome; glucagon like; transporter inhibitors ... See more keywords
Increased risk of mycotic infections associated with sodium–glucose co‐transporter 2 inhibitors: a prescription sequence symmetry analysis
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13782
Abstract: To determine the risk of mycotic infections associated with the use of sodium–glucose co‐transporter 2 inhibitors (SGLT2i) in a real‐world setting. read more here.
Keywords: sodium glucose; glucose transporter; risk mycotic; mycotic infections ... See more keywords
Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Pharmacology"
DOI: 10.1111/bph.15850
Abstract: Sodium glucose co‐transporter 2 inhibitors (SGLT‐2is) improve cardiovascular outcomes in both diabetic and non‐diabetic patients. Preclinical studies suggest that SGLT‐2is directly affect endothelial function in a glucose‐independent manner. The effects of SGLT‐2is include decreased oxidative… read more here.
Keywords: sglt 2is; glucose transporter; sodium; transporter inhibitors ... See more keywords
Sodium‐glucose co‐transporter‐2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13142
Abstract: Cardiovascular disease remains the main cause of morbidity and mortality in people with diabetes, and is also the largest contributor to healthcare costs in this population(1). read more here.
Keywords: sodium glucose; glucose transporter; inhibitors cardiovascular; outcome studies ... See more keywords
Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes"
DOI: 10.1111/dom.14986
Abstract: To determine whether the magnitude of the cardiorenal benefits of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) varies with baseline kidney function. read more here.
Keywords: glucose transporter; kidney function; transporter inhibitors; baseline kidney ... See more keywords